1 / 20

MRSA In The Past Decade

MRSA In The Past Decade. Topics. Microbiology of S.aureus Community-acquired MRSA Vancomycin-resistant MRSA Antibiotic selections Others: MRSA vaccine, nasal carriage and effect of mupirocin . Structure of S.aureus. Panton-Valentine Leukocidin.

kamil
Download Presentation

MRSA In The Past Decade

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MRSAIn The Past Decade

  2. Topics • Microbiology of S.aureus • Community-acquired MRSA • Vancomycin-resistant MRSA • Antibiotic selections • Others: MRSA vaccine, nasal carriage and effect of mupirocin

  3. Structure of S.aureus. Panton-Valentine Leukocidin Microbial surface components recognizing adhesive matrix molecules (MSCRAMM)

  4. Comparison of Nosocomial (Health care associated) and Community - Acquired MRSA Bartlett JG. www.medscape;May 2004

  5. 2002

  6. Vancomycin-intermediate S.aureus • 1988 VRE carrying vanA gene reported in France • 1992 In-vitro transfer of vanA determinant from E.faecalis to S.aureus • 1997 First strain of S.aureus with reduced susceptibility to vancomycin and Teicoplanin reported in Japan

  7. Vancomycin-intermediate S.aureus in the United States 1 Smith TL, et al NEJM 1999;340:493-501. 2 Rotunss, et al EID 1999;5:147-9. 3 MMWR 2000;48:1165-7. 4 Unpublished data (CDC, State Health Department) Fridkin SK. CID 2001;32:108-15

  8. Vancomycin-resistant S.aureus • From 1997-present VISA: Japan, U.S., France, U.K., Germany, Korea Hetero-VRSA: Spain, Scotland, Hong Kong, Germany, Netherland, Poland, Greece and Thailand • June 2002, First vanA containing VRSA isolated from a dialysis patient in Michigan, U.S. • August 2002, Second VRSA isolate from Pennsylvania, U.S.

  9. Nomenclature • VISA Vancomycin-intermediate S.aureus • GISA Glycopeptide-intermediate S.aureus • VRSA Vancomycin-resistant S.aureus • hVRSA or hVISA Heteroresistant-VRSA • SA-RVS S.aureus with reduced vancomycin susceptibility

  10. Vancomycin Interpretive Criteria aNCCLS, National Committee for Clinical Laboratory Standards; CA-SFM, Comité de I’Antibiogramme de la Société Française Microbiologie; BSAC, British Society for Antimicrobial Chemotherapy.

  11. Hetero-VRSA • Definition: S.aureus strains that contain subpopulation of vancomycin-resistant daughter cells but for which the MICs of vancomycin for the parent strain are only 1-4 μg/ml. • Identified by growth on BHI screening agar containing vancomycin (4-6 μg/ml), when selected and tested , MICs 2-8 fold higher than original strain. • Population analysis is the standard method of identification (Prototype, Mu3)

  12. Population Analysis Mu50: VRSA, Mu3: hetero-VRSA, H1:MRSA, FDA209P:MSSA

  13. Mechanisms of Vancomycin Resistance • Excess production of peptidoglycan • Reduction of peptidoglycan turnover • Reduction of autolytic activity • Decrease in intracellular glutamine level • Decrease of cross-linkage of peptidoglycan • Abnormal production of murein monomer leading to increased proportion of D-alanyl-D-alanine residues in the peptidoglycan level Still Poorly Understood

  14. Cell wall thickness as a contributor of vancomycin resistance Affinity Trapping & Clogging Phenomenon Hiramatsu K. Lancet Inf Dis 2001;1:127-155

  15. Cell Wall Thickening by Transmission Electron Microscopy Parental MRSA Induced hetero-VRSA

  16. Algorithm for Testing S. aureus with Vancomycin (VA) Acceptable Primary Test Methods Include: April 2004 MIC method1plus VA screen plate (BHIA with 6 µg/ml of VA) Disk diffusion2plus VA screen plate (BHIA with 6 µg/ml of VA) VA zone <14 mm AND GROWTH on VA screen plate VA zone >14 mm AND GROWTH on VA screen plate VA MIC <2 µg/ml And NO growth on VA screen plate VA MIC <2 µg/ml AND GROWTH on VA screen plate (rare) VA MIC >4 µg/ml AND GROWTH on VA screen plate VA zone >14 mm and NO growth on VA screen plate Possible VISA/VRSA Possible VISA/VRSA Report as VSSA3 Report as VSSA3 CHECK purity CONFIRM isolate ID RETEST using non-automated MIC method4 SAVE ISOLATE NOTIFY infection control, physician, local health department and CDC5 of “possible VISA/VRSA” SEND to reference laboratory for confirmation Important Footnotes 1Laboratories using automated susceptibility test methods should add a commercial vancomycin agar screen plate. 2Disk diffusion alone is not sufficient to detect VISA. 3If a laboratory is concerned about a result based on a patient’s history, MIC testing can be performed at CDC. 4 Non-automated methods: reference broth microdilution, agar dilution, agar gradient diffusion (Etest; use a 0.5 McFarland inoculum and Mueller-Hinton agar). 5Report to CDC by email: SEARCH@cdc.gov More VISA/VRSA info: www.cdc.gov/ncidod/hip/vanco/vanco.htm

  17. Alternatives to Vancomycin for MRSA Infection Bartlett JG. www.medscape;May 2004

  18. 100 80 MRSA46 60 MRSA47 MSSA46 40 MSSA47 20 0 AMC SXT FOS OXA TEI CLI ERY GEN PEN VAN แผนภูมิแสดงร้อยละของเชื้อ MRSA และ MSSA ที่ไวต่อยาต้านจุลชีพ ที่ทดสอบ 10 ชนิด ในปี พ.ศ. 2546-47 http://narst.dmsc.moph.go.th

  19. Other Topics • S.aureus bacteremia appear to be of endogenous origin in the nasal mucosa. (Von Eiff C, et al. NEJM 2001;344:11-6) • Prophylactic intranasal application of mupirocin did not significantly reduce S.aureus surgical-site infection rate, but decrease nosocomial S.aureus infections. (Perl TM, et al. NEJM 2002;346: 1871-7) • Bivalent conjugate S.aureus type 5,8 vaccine confered partial immunity. (Shinfield H, et al. NEJM 2002;346:491-6)

  20. Conclusion Nature is always at least ahead of science. • Continuing research on pathogenesis • Future vaccine? • Continuing new drugs development • Prevention is the key. • Need stringent infection control

More Related